Content & Events
Careers
Investors
Contact
About
+
-
Get To Know Us
Leadership Team
Board Of Directors
Commercial & PM Teams
A Welcoming CDMO: It's The Texas In Us
Careers
Clinical Biomanufacturing
+
-
Clinical Biomanufacturing
+
-
cGMP Mammalian Cell Culture
cGMP Microbial Fermentation
Process Development
+
-
Mammalian Cell Culture Development
Cell Therapy Development
Microbial Fermentation Development
Downstream Process Development
Formulation Development
Commercial Manufacturing
Bioanalytical Services
+
-
Methods Development
Technologies
Pre-Clinical & Product Development Services
+
-
Toxicokinetic Studies (TK)
Comprehensive Immune Profiling
Cell-Based Potency Assays
CMC Analytical Support Services
+
-
Release Testing
Stability Testing
Bioassays
Content & Events
Careers
Investors
Contact
News | Scorpius
All Media
News
Events
Articles
Blogs
Resources
Videos
news
Scorpius BioManufacturing Appoints New VP of Business Development Shari Udoff-McDonald
Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), appointed a new VP of Business Development Shari Udoff-McDonald.
May 6, 2024
NightHawk Biosciences Completes Name Change to Scorpius Holdings
NightHawk Biosciences announced its name change to Scorpius Holdings, Inc., to better reflect the company’s successful shift into a pure-play, large molecule biomanufacturing CDMO.
February 6, 2024
news
Scorpius BioManufacturing Announces Joe Payne as President and Chief Operating Officer
Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), promoted Joe Payne to President and COO.
February 1, 2024
news
Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM₁₉₇
Fina Biosolutions has selected Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM
197
conjugate ...
July 27, 2023
news
Scorpius Expands Leadership Team With New VP, Manufacturing Operations
Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), expanded its leadership to include Matthew R. LeClair.
July 7, 2023